Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: A randomized open-label, noninferiority trial, MONOI-ANRS 136

AIDS

Volumn 24, Issue 15, 2010, Pages 2365-2374

  Katlama, Christine ^a,b   Valantin, Marc A ^a,b   Algarte Genin, Michele ^a   Duvivier, Claudine ^c   Lambert Niclot, Sidonie ^a,d   Girard, Pierre M ^e   Molina, Jean M ^b   Hoen, Bruno ^f   Pakianather, Sophie ^a   Peytavin, Gilles ^g   Marcelin, Anne G ^a,d   Flandre, Philippe ^a,d  

^a INSERM   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e HÔPITAL SAINT ANTOINE   (France)

^f Department of Infectious Diseases   (France)

^g BICHAT HOSPITAL   (France)

Author keywords

darunavir; HIV suppressed viremia; maintenance therapy; protease inhibitor monotherapy

Indexed keywords

ABACAVIR; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ZIDOVUDINE;

ADD ON THERAPY; ADULT; ARTICLE; ASTHENIA; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INFECTION; LIPODYSTROPHY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS INHIBITION; VIRUS LOAD;

ADULT; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RITONAVIR; RNA, VIRAL; SULFONAMIDES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77957230936     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833dec20     Document Type: Article

References (30)

1. Clumeck N, Pozniak A, Raffi F and EACS executive committee. European AIDS Clinical Society (EACS) Guidelines for the Clinical Management and Treatment of HIV infected adults. HIV Med 2008; 9:65-71 (Pubitemid 351228129)
2. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d?Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29. (Pubitemid 36835816)
3. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12:1735-1744. (Pubitemid 28454438)
4. Calmy A, Gayet-Ageron A, Montecucco F, Nguyen A, Mach F, Burger F, et al. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 2009; 23:929-939.
5. Choi AI, Shlipak MG, Hunt PW, Martin JN, Deeks SG. HIVinfected persons continue to lose kidney function despite successful antiretroviral therapy. AIDS 2009; 23:2143-2149.
6. Martin A, Smith DE, Carr A, Ringland C, Amin J, Emery S, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension study. AIDS 2004; 18:1029-1036. (Pubitemid 38591194)
7. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4R count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296. (Pubitemid 44837777)
8. Cameron DW, da Silva BA, Arribas JR, Myers RA, Bellos NC, Gilmore N, et al. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis 2008; 198:234-240. (Pubitemid 352019289)
9. Campo RE, Lalanne R, Tanner TJ, Jayaweera DT, Rodriguez AE, Fontaine L, Kolber MA. Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients. AIDS 2005; 19:447-449. (Pubitemid 40446194)
10. Pulido F, Perez-Valero I, Delgado R, Arranz A, Pasquau J, Portilla J, et al. Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Antivir Ther 2009; 14:195-201.
11. Wilkin TJ, McKinnon JE, DiRienzo AG, Mollan K, Fletcher CV, Margolis DM, et al. Regimen simplification to atazanavirritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. J Infect Dis 2009; 199:866-871.
12. Schackman BR, Scott CA, Sax PE, Losina E, Wilkin TJ, McKinnon JE, et al. Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clin Infect Dis 2007; 45:1062-1070. (Pubitemid 47580359)
13. De Meyer S, Lathouwers E, Dierynck I, De Paepe E, Van Baelen B, Vangeneugden T, et al. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. AIDS 2009; 23:1829-1840.
14. Katlama C, Esposito R, Gatell JM, Goffard JC, Grinsztejn B, Pozniak A, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007; 21:395-402. (Pubitemid 46263249)
15. Yilmaz A, Izadkhashti A, Price RW, Mallon PW, De Meulder M, Timmerman P, Gisslen M. Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. AIDS Res Hum Retroviruses 2009; 25:457-461.
16. Boffito M, Miralles D, Hill A. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100mg once-daily in treatment-naive and -experienced patients. HIV Clin Trials 2008; 9:418-427.
17. Pulido F, Arribas JR, Delgado R, Cabrero E, Gonzalez-Garcia J, Perez-Elias MJ, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS 2008; 22:F1-9.
18. Ribaudo H LJ, Currier J, Kuritzkes D, Gulick R, Haubrich M, et al. Virologic failure endpoint definition in clinical trials: is using HIV-1 RNA threshold >200 copies/mL better than >50 copies/mL? An analysis of ACTG studies [abstract 580]. 16th Conference on Retroviruses and Opportunistic Infections; Montreal, Canada; February 2009.
19. De Meyer S, Azijn H, Surleraux D, Jochmans D, Tahri A, Pauwels R, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005; 49:2314?2321. (Pubitemid 40734460)
20. Surleraux DL, de Kock HA, Verschueren WG, Pille GM, Maes LJ, Peeters A, et al. Design of HIV-1 protease inhibitors active on multidrug-resistant virus. J Med Chem 2005; 48: 1965?1973. (Pubitemid 40403065)
21. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008; 16:138-145.
22. Carrieri P, Cailleton V, Le Moing V, Spire B, Dellamonica P, Bouvet E, et al. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. J Acquir Immune Defic Syndr 2001; 28:232-239. (Pubitemid 33055448)
23. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006; 295:1152-1160. (Pubitemid 43352345)
24. Arribas JR, Horban A, Gerstoft J, Fatkenheuer G, Nelson M, Clumeck N, et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 2010; 24:223-230.
25. Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361:2230-2240.
26. Delfraissy JF, Flandre P, Delaugerre C, Ghosn J, Horban A, Girard PM, et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIVinfected patients. AIDS 2008; 22:385-393.
27. Delaugerre C, Flandre P, Chaix ML, Ghosn J, Raffi F, Dellamonica P, et al. Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy. Antimicrob Agents Chemother 2009; 53:2934-2939.
28. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-2106. (Pubitemid 351679596)
29. Flandre P, Delaugerre C, Ghosn J, Chaix ML, Horban A, Girard PM, et al. Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK trial randomized to ritonavir-boosted lopinavir alone. Antivir Ther 2009; 14:93-97.
30. Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG, et al. Discordance between CSF and plasma HIV replication in patients with neurological symptoms and suppressive antiretroviral therapy. Clin Infect Dis 2010; 50:773-778.